

HUA MEDICINE
華領醫藥

( )

(於百慕達註冊成立之有限公司)
(Stock code 股份代號：2552)

NOTIFICATION LETTER 通知信函

23 April 2026

Dear Non-registered Holder(s) [1],

Hua Medicine (the "Company")
– Notice of publication of Annual Report 2025, Circular in relation to proposals for re-election of retiring directors, general mandates to repurchase and issue shares, re-appointment of auditor, adoption of new Memorandum and Articles of Association and notice of annual general meeting and Proxy Form (the "Current Corporate Communication

REQUEST FORM 申請表格

To: **Hua Medicine (the "Company")**
(Stock Code: 2552)
(**)**
c/o Tricor Investor Services Limited
17/F, Far East Finance Centre,
16 Harcourt Road, Hong Kong

致： **華領醫藥(「本公司」)**
(股份代號：2552)
(於開曼群島註冊成立的有限公司)
經卓佳證券登記有限公司
香港夏慤道16號
遠東金融中心17樓

REMINDER 提示

As a non-registered holder, if you wish to receive Corporate Communications(1) pursuant to the Listing Rules(2), you should liaise with your bank(s), broker(s), custodian(s), nominee(s) or HKSCC Nominees Limited through which your shares are held (collectively, the "Intermediaries") and provide your email address to your Intermediaries.
作為非登記股東，如有意根據《上市規則》(2)收取公司通訊(1)，閣下應聯絡閣下持有股份的銀行、經紀、託管商、代理人或香港中央結算(代理人)有限公司(統稱「中介公司」)，並向閣下的中介公司提供閣下的電子郵件地址。

I/We would like to receive the Current Corporate Communications and all future Corporate Communications of the Company in the manner as indicated below:
本人／我們現在希望以下列方式收取本公司本次及將來所有公司通訊文件：

(Please mark a "✓" in ONLY ONE of the following boxes)(請從下列選擇中，**僅**在其中**一個空格**內劃上「✓」號)

☐ **to receive a printed copy in the English language only; OR**
僅收取**英文**印刷本；**或**

☐ **to receive a printed copy in the Chinese language only; OR**
僅收取**中文**印刷本；**或**

☐ **to receive a printed copy in both the English language and the Chinese language.**
同時收取**英文及中文**印刷本。

Signature:
簽署：

Date:
日期：

Name:
姓名：(**English** 英文)
*(**in block letters** 請以正楷填寫)*

Contact Phone Number:
聯絡電話：

Postal Address
郵寄地址：(**English** 英文)
*(**in block letters** 請以正楷填寫)*

Notes 附註：
1. Corporate Communications include any document(s) issued or to be issued by the Company for the information or action of holders of any of its securities or the investing public, including but not limited to (a) the directors' report and